Table 2.
Baseline characteristics
| Standard of care (N = 31) |
Alirocumab (N = 30) |
|
|---|---|---|
| Age, yrs | 61.3 ± 9.9 | 61.3 ± 8.9 |
| Male | 74.2 (23) | 66.7 (20) |
| Diabetes | 25.8 (8) | 23.3 (7) |
| Current smoker | 25.8 (8) | 30 (9) |
| Hypertension | 61.3 (19) | 56.7 (17) |
| Prior MI | 9.7 (3) | 13.3 (4) |
| Prior stroke | 3.2 (1) | 10.0 (3) |
| ACS | 41.9 (13) | 36.7 (11) |
| Antiplatelet | 100 (31) | 100 (30) |
| Beta-blocker | 90.3 (28) | 93.3 (28) |
| ACEI/ARB | 64.5 (20) | 60.0 (18) |
| Chronic statin before enrollment | 32.3 (10) | 26.7 (8) |
| Imaged artery | ||
| Left anterior desending | 41.9 (13) | 43.3 (13) |
| Left circumflex | 22.6 (7) | 26.7 (8) |
| Right coronary | 32.2 (10) | 30.0 (9) |
| Others | 3.2 (1) | 0 |
ACS acute coronary syndrome, MI myocardial infarction, ACEI/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers